logo

Aldeyra Therapeutics, Inc. (ALDX)



Trade ALDX now with
  Date
  Headline
1/11/2022 8:10:56 AM Aldeyra Announces Positive Data From Phase 2 Dry Eye Chamber Trial Of Reproxalap Vs. Xiidra
1/4/2022 8:10:13 AM Aldeyra Completes Enrollment In Part 1 Of Phase 3 Trial of ADX-2191 In Proliferative Vitreoretinopathy
11/9/2021 8:14:42 AM Aldeyra Therapeutics Completes Enrollment In Phase 3 TRANQUILITY Trial In Patients With Dry Eye Disease
11/2/2021 8:28:41 AM Aldeyra Therapeutics Achieves Primary Endpoint Of Ocular Redness In Phase 2 Clinical Trial In Dry Eye Disease
10/28/2021 7:41:03 AM Aldeyra Therapeutics Q3 Net Loss $15.8 Mln Vs Net Loss $8.9 Mln Last Year
8/5/2021 7:19:22 AM Aldeyra Therapeutics Q2 Net Loss $14.9 Mln Vs Net Loss $7.5 Mln Last Year
8/4/2021 8:07:51 AM Aldeyra Receives Orphan Drug Designation From FDA For ADX-2191 To Treat Retinitis Pigmentosa
7/20/2021 8:04:52 AM Aldeyra Therapeutics Says Gets Orphan Drug Designation From US FDA For ADX-2191 To Treat Primary Vitreoretinal Lymphoma
4/27/2021 7:55:51 AM Aldeyra Achieves Primary Endpoint And All Secondary Endpoints In Phase 3 Trial Of Reproxalap In Allergic Conjunctivitis
3/11/2021 7:12:40 AM Aldeyra Therapeutics Net Loss For Full-year 2020 $37.6 Mln Or $1.11 Per Share
1/20/2021 7:08:54 AM Aldeyra Therapeutics Announces Closing Of Underwritten Public Offering Of 7.87 Mln Shares At $9.50/shr
1/13/2021 4:05:24 PM Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
1/7/2021 7:04:32 AM Aldeyra Announces Positive Top-Line Results From Run-In Cohort Of Phase 3 TRANQUILITY Trial In Dry Eye Disease